Ivonescimab’s Western Survival Signal Strengthens

Company Summit Therapeutics / Akeso Event Type Clinical Trial Update (Phase 3, Updated Survival Analysis) Modality Bispecific Antibody (PD-1 x VEGF) Asset Ivonescimab Target PD-1 / VEGF Disease Area EGFR-Mutated Non-Small Cell Lung Cancer Summary Summit reported an updated overall-survival hazard ratio of 0.76 for…